Pakistan’s Pharma Growth |
Pakistan's pharmaceutical industry, with more than 700 registered pharmaceutical companies, has quietly reached a landmark that deserves far greater public attention. For the first time in its history, the sector has crossed PKR 1 trillion in annual revenues, reflecting not only its growing economic significance but also its strategic importance for national healthcare, industrial development, and exports. This milestone is more than a financial achievement. It signals a structural transformation in an industry that has long struggled with inflation, currency depreciation, supply chain disruptions, and pricing constraints. The recent deregulation of prices for non-essential medicines has reshaped the financial landscape, allowing pharmaceutical manufacturers to absorb rising production costs while strengthening their ability to invest in research, technology, and expansion.
From a medical professional’s perspective, the industry’s evolution is both encouraging and instructive. A review of trailing twelve-month financial data, fiscal performance, and reports from the Pakistan Credit Rating Agency, Topline Securities, Pakistan Stock Exchange, and IQVIA retail market audits reveals that Pakistan’s pharmaceutical market continues to operate as an oligopoly. Although more than 650 pharmaceutical manufacturers are registered in the country, the top ten companies continue to command an overwhelming share of the market through their established brands, extensive distribution networks, and manufacturing capabilities. One of the most significant catalysts behind the sector’s improved performance has been the government’s decision to deregulate prices for non-essential medicines. For years, pharmaceutical manufacturers struggled to cope with soaring costs of imported raw materials, energy,........